original ) (raw )Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination
frank graham
Gene Therapy, 1997
View PDFchevron_right
INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies
Károly Antal Tóth
Cancer Gene Therapy, 2009
View PDFchevron_right
Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model
Hugo Barrera-saldaña
Molecular therapy : the journal of the American Society of Gene Therapy, 2002
View PDFchevron_right
Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy
Yaohe Wang , Gunnel Hallden
Molecular Therapy, 2003
View PDFchevron_right
Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir
Vincenzo Cerullo , Rubén Hernández-alcoceba
The Journal of Gene Medicine, 2010
View PDFchevron_right
Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector
frank graham
Mol. Med, 2000
View PDFchevron_right
Immunosuppression enhances oncolytic adenovirus replication and anti tumor efficacy in the Syrian hamster model
N. Phillips
View PDFchevron_right
Impact of Human Neutralizing Antibodies on Antitumor Efficacy of an Oncolytic Adenovirus in a Murine Model
Daniel Maneval
Clinical Cancer Research, 2004
View PDFchevron_right
Immunocompetent Syngeneic Cotton Rat Tumor Models for the Assessment of Replication-Competent Oncolytic Adenovirus
Brian Morrison
View PDFchevron_right
Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications
James Davies
Viruses, 2015
View PDFchevron_right
Rodents Versus Pig Model for Assessing the Performance of Serotype Chimeric Ad5/3 Oncolytic Adenoviruses
Richard Bianco
Cancers, 2019
View PDFchevron_right
Species D Adenoviruses as Oncolytic Viral Vectors
Brigette Corder
Viruses, 2020
View PDFchevron_right
The efficacy of oncolytic adenovirus is mediated by T cell responses against virus and tumor in Syrian hamster model
Yaohe Wang
Clinical cancer research : an official journal of the American Association for Cancer Research, 2016
View PDFchevron_right
Sequential administration of bovine and human adenovirus vectors to overcome vector immunity in an immunocompetent mouse model of breast cancer
Anurag Sharma
Virus Research, 2012
View PDFchevron_right
Concepts in Oncolytic Adenovirus Therapy
dongbiao wang
International Journal of Molecular Sciences, 2021
View PDFchevron_right
A Novel Ex vivo Model System for Evaluation of Conditionally Replicative Adenoviruses Therapeutic Efficacy and Toxicity
Minghui Wang
2004
View PDFchevron_right
High-dose chemotherapy augments the efficacy of recombinant adenovirus vaccines and improves the therapeutic outcome
Danny Bernard
Cancer Gene Therapy, 2009
View PDFchevron_right
Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model
Anurag Sharma
Virus Research, 2010
View PDFchevron_right
Evaluation of the Biodistribution, Persistence, Toxicity, and Potential of Germ-Line Transmission of a Replication-Competent Human Adenovirus Following Intraprostatic Administration in the Mouse
Joe Hughes
Molecular Therapy, 2000
View PDFchevron_right
Role of Adenoviruses in Cancer Therapy
SINTAYEHU TSEHA
Frontiers in Oncology
View PDFchevron_right
Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus
Terry Hermiston
Molecular Therapy - Oncolytics, 2017
View PDFchevron_right
Adenovirus Biodistribution is Modified in Sensitive Animals Compared to Naïve Animals
Juan Armendáriz-Borunda
Molecular Biotechnology, 2020
View PDFchevron_right
Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches
Masoud Najafi
View PDFchevron_right